← Back to Search

Intraocular Lens

New Lens for Cataracts

N/A

Waitlist Available

Research Sponsored by Alcon Research

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Planned cataract surgery (both eyes)

Be older than 18 years old

Must not have

Women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 2 postoperative

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if a new type of lens, called Clareon™ PanOptix™ Pro Trifocal Intraocular Lens, is both safe and works well compared to the standard Clare

Who is the study for?

This trial is for adults who need cataract surgery in both eyes, can follow the study schedule, and have less than 1.00 diopter of preoperative corneal astigmatism. It's not for pregnant or breastfeeding women, those wanting monovision correction, or anyone with certain eye conditions.

What is being tested?

The study compares two types of trifocal lenses: Clareon PanOptix Pro IOL and Clareon PanOptix IOL. Participants will receive one type of lens during their planned cataract surgery to see which is safer and more effective.

What are the potential side effects?

Potential side effects may include visual disturbances like glare or halos around lights, discomfort in the eye, inflammation or infection risk post-surgery. Specific side effects related to each lens type will be monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am scheduled for cataract surgery on both eyes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not pregnant, do not plan to become pregnant, and am not breastfeeding.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 2 postoperative

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 2 postoperative

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 2 postoperative for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: CPO Pro IOLExperimental Treatment3 Interventions

CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.

Group II: CPO IOLExperimental Treatment3 Interventions

CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cataract Surgery

2010

Completed Phase 4

~5370

0 / 2Eligibility criteria met